Psychoses Clinical Trial
Official title:
Oxidative Cell Injury: First Episode Psychotic Patients
Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences in their blood that reflect oxidative brain cell damage.
Status | Completed |
Enrollment | 30 |
Est. completion date | August 2004 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 12 Years to 45 Years |
Eligibility |
Inclusion Criteria - Patients must meet clinical diagnostic criteria for psychosis - Healthy (control) volunteers must not have any family history of mental illness |
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal
Country | Name | City | State |
---|---|---|---|
United States | Medical College of Georgia | Augusta | Georgia |
Lead Sponsor | Collaborator |
---|---|
National Center for Complementary and Integrative Health (NCCIH) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01196858 -
Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland
|
N/A | |
Completed |
NCT00159120 -
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
|
Phase 4 | |
Completed |
NCT00159133 -
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
|
Phase 4 | |
Completed |
NCT00087542 -
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
|
Phase 2 | |
Completed |
NCT00095810 -
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
|
Phase 4 | |
Recruiting |
NCT00752960 -
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
|
N/A | |
Completed |
NCT00469365 -
Pharmacy Interventions to Improve Chronic Disease Medication Refill
|
Phase 3 | |
Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
Completed |
NCT00204061 -
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
|
Phase 4 | |
Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
Active, not recruiting |
NCT00260273 -
Access, Detection and Psychological Treatments
|
N/A | |
Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
Completed |
NCT03609515 -
Patient-controlled Admissions in Inpatient Mental Health Services
|
N/A |